Beijing SL Pharmaceutical Co Ltd. has developed a new drug combining Lenalidomide and Dasatinib, which are both used as treatments for cancer patients.

The company owns the property rights of the new product and a share of the global market sales.

SL Pharmaceutical is also negotiating patent licenses with internationally renowned pharmaceutical companies to sell the new drug internationally, and the company is expected to serve as a model for domestic pharmaceutical companies.

Lenalidomide is used in the treatment of myeloma, Dasatinib is used to treat leukemia, and both these drugs are produced and used in large amounts worldwide.

Edited by Niva Whyman